An Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SKLB1028 in Patients With Advanced Solid Tumors
Latest Information Update: 05 Oct 2023
At a glance
- Drugs SKLB 1028 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 13 Oct 2021 New trial record